GlassScriptPhysician profile
Kenneth Borkowski
NPI 1730102260
$5,286.23
in general payments reported to CMS, 2019-2025
30 companies · $961 in 2025
The $961 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $324 · 2021: $724 · 2022: $963 · 2023: $1,137 · 2024: $885 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.55 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.67 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Mayne Pharma Commercial LLC | $736.66 | 2021-2025 | |
| Astellas Pharma US INC | $406.46 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $382.38 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $353.38 | 2019-2022 | |
| Avion Pharmaceuticals | $322.87 | 2019-2021 | |
| Sage Therapeutics, LLC | $285.16 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $225.37 | 2019-2025 | Slynd |
| Pfizer INC. | $196.92 | 2022-2024 | |
| Millicent US INC | $195.51 | 2019-2025 | Femlyv, Femring, Intrarosa |
| Caldera Medical, INC | $159.56 | 2024 | Desara |
| Bayer Healthcare Pharmaceuticals INC. | $158.48 | 2021-2025 | |
| Myovant Sciences INC. | $153.72 | 2021-2022 | |
| Exact Sciences Corporation | $117.31 | 2023-2025 | Cologuard Collection Kit |
| Shionogi INC | $101.68 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $96.90 | 2021-2023 | Twirla |
| Coopersurgical, INC. | $79.29 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Organon LLC | $62.75 | 2022-2025 | Nexplanon |
| Supernus Pharmaceuticals, INC. | $38.17 | 2025 | Qelbree |
| Mylan Pharmaceuticals INC. | $35.21 | 2021 | |
| Medicem INC. | $31.59 | 2021 | |
| Aspira Women'S Health INC | $29.51 | 2024 | Ova1 |
| Lupin INC. | $27.87 | 2019-2020 | |
| Duchesnay USA Incorporated | $23.91 | 2019 | |
| Minerva Surgical, INC | $22.67 | 2021 | |
| Evofem Biosciences, INC. | $21.86 | 2021 | |
| Shield Therapeutics INC | $18.97 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $17.87 | 2025 | Gardasil 9 |
| Allergan, INC. | $17.50 | 2020 | |
| Amag Pharmaceuticals, INC. | $15.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Borkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.